Living Without Blockbuster  

Oleh:

Herper, Matthew

Jenis: Article from Bulletin/Magazine
Dalam koleksi: Forbes Asia vol. 5 no. 17 (Nov. 2009), page 82-83.
Topik: Drugmaker Company; Paris; Sanofi-Aventis; Sanofi-Synthelabo; Acquisition; Research Spending

Ketersediaan

Perpustakaan Pusat (Semanggi) Nomor Panggil: FF5.1 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Christopher Viehbacher, the chief of drugmaker Sanofi-Aventis, is slashing research spending and moving into emerging countries. Viehbacher, 49, is out to change the $37 billion (2008 sales) company, created in the 2004 acquisition of Aventis by Sanofi-Synthelabo. One of his first acts was to move the earnings calls to the afternoon Paris time. When the drugs safety police this year linked Lantus, the company's $4-billion-a-year long-lasting insulin, to cancer, he responded quickly, assembling a committee of experts on diabetes and tumors to refute the connection.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali